{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:37:14Z","timestamp":1790800634278,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K12 CA184746"],"award-info":[{"award-number":["K12 CA184746"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA192937"],"award-info":[{"award-number":["P50 CA192937"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00259-021-05386-0","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T19:02:17Z","timestamp":1620500537000},"page":"3940-3950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prognostic value of [18F]FDG PET\/CT in patients with CNS lymphoma receiving ibrutinib-based therapies"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-4531","authenticated-orcid":false,"given":"Simone","family":"Krebs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-6093","authenticated-orcid":false,"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0252-0694","authenticated-orcid":false,"given":"Vaios","family":"Hatzoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4664-670X","authenticated-orcid":false,"given":"Lauren R.","family":"Schaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-8149","authenticated-orcid":false,"given":"Ingo K.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-4185","authenticated-orcid":false,"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-0441","authenticated-orcid":false,"given":"Christian","family":"Grommes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"issue":"suppl_5","key":"5386_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/now207","volume":"18","author":"QT Ostrom","year":"2016","unstructured":"Ostrom QT, Gittleman H, Xu J, et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2009\u20132013. Neuro-Oncol. 2016;18(suppl_5):v1\u2013v75.","journal-title":"Neuro-Oncol"},{"issue":"5","key":"5386_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncol. 2018;20(5):687\u201394.","journal-title":"Neuro-Oncol."},{"issue":"5","key":"5386_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/ajcp\/110.5.607","volume":"110","author":"S Camilleri-Bro\u00ebt","year":"1998","unstructured":"Camilleri-Bro\u00ebt S, Martin A, Moreau A, et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d\u2019\u00e9tude des Leuc\u00e9nies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. 1998;110(5):607\u201312.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"5386_CR4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436\u201347.","journal-title":"Ann Oncol"},{"issue":"27","key":"5386_CR5","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5386_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11060-017-2686-3","volume":"136","author":"D Albano","year":"2018","unstructured":"Albano D, Bosio G, Bertoli M, Giubbini R, Bertagna F. 18F-FDG PET\/CT in primary brain lymphoma. J Neuro-Oncol. 2018;136(3):577\u201383.","journal-title":"J Neuro-Oncol"},{"issue":"8","key":"5386_CR7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","volume":"32","author":"D Albano","year":"2018","unstructured":"Albano D, Bertoli M, Battistotti M, et al. Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma. Ann Nucl Med. 2018;32(8):532\u201341.","journal-title":"Ann Nucl Med"},{"issue":"21","key":"5386_CR8","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"5386_CR9","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018\u201329.","journal-title":"Cancer Discov"},{"issue":"5","key":"5386_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","volume":"133","author":"C Grommes","year":"2019","unstructured":"Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood. 2019;133(5):436\u201345.","journal-title":"Blood."},{"issue":"6","key":"5386_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833\u2013843.e835.","journal-title":"Cancer Cell"},{"key":"5386_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121\u201330.","journal-title":"Eur J Cancer"},{"issue":"22","key":"5386_CR13","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034\u201343.","journal-title":"J Clin Oncol"},{"issue":"12 Suppl","key":"5386_CR14","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F","volume":"80","author":"YE Erdi","year":"1997","unstructured":"Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80(12 Suppl):2505\u20139.","journal-title":"Cancer."},{"issue":"2","key":"5386_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11060-018-2960-z","volume":"140","author":"V Hatzoglou","year":"2018","unstructured":"Hatzoglou V, Oh JH, Buck O, et al. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma. J Neuro-Oncol. 2018;140(2):351\u20138.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"5386_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02294183","volume":"65","author":"DG Bonett","year":"2000","unstructured":"Bonett DG, Wright TA. Sample size requirements for estimating Pearson, Kendall and Spearman correlations. Psychometrika. 2000;65(1):23\u20138.","journal-title":"Psychometrika."},{"issue":"36","key":"5386_CR17","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711\u20135.","journal-title":"J Clin Oncol"},{"issue":"8","key":"5386_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1704610","volume":"377","author":"JS Abramson","year":"2017","unstructured":"Abramson JS, McGree B, Noyes S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377(8):783\u20134.","journal-title":"N Engl J Med"},{"issue":"11","key":"5386_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","volume":"134","author":"MJ Frigault","year":"2019","unstructured":"Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860\u20136.","journal-title":"Blood."},{"issue":"25","key":"5386_CR20","doi-asserted-by":"publisher","first-page":"41518","DOI":"10.18632\/oncotarget.17456","volume":"8","author":"Y Zou","year":"2017","unstructured":"Zou Y, Tong J, Leng H, Jiang J, Pan M, Chen Z. Diagnostic value of using 18F-FDG PET and PET\/CT in immunocompetent patients with primary central nervous system lymphoma: a systematic review and meta-analysis. Oncotarget. 2017;8(25):41518\u201328.","journal-title":"Oncotarget."},{"issue":"11","key":"5386_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.medcli.2014.09.010","volume":"144","author":"S Mercadal","year":"2015","unstructured":"Mercadal S, Cort\u00e9s-Romera M, V\u00e9lez P, Climent F, G\u00e1mez C, Gonz\u00e1lez-Barca E. Positron emission tomography combined with computed tomography in the initial evaluation and response assessment in primary central nervous system lymphoma. Med Clin. 2015;144(11):503\u20136.","journal-title":"Med Clin"},{"key":"5386_CR22","doi-asserted-by":"crossref","unstructured":"Herhaus P, Lipkova J, Lammer F, et al. CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma. J Nucl Med. 2020;61(12):1765\u201371.","DOI":"10.2967\/jnumed.120.241703"},{"key":"5386_CR23","doi-asserted-by":"publisher","unstructured":"Clarke BN. PET radiopharmaceuticals: what\u2019s new, what\u2019s reimbursed, and what\u2019s next? J Nucl Med Technol. 2018. https:\/\/doi.org\/10.2967\/jnmt.117.205021.","DOI":"10.2967\/jnmt.117.205021"},{"issue":"16","key":"5386_CR24","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Cottereau AS, Casasnovas O, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135(16):1396\u2013405.","journal-title":"Blood."},{"issue":"6","key":"5386_CR25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1182\/bloodadvances.2019001201","volume":"4","author":"L Ceriani","year":"2020","unstructured":"Ceriani L, Gritti G, Cascione L, et al. SAKK38\/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv. 2020;4(6):1082\u201392.","journal-title":"Blood Adv"},{"issue":"1","key":"5386_CR26","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.3324\/haematol.2019.223016","volume":"105","author":"C Bailly","year":"2020","unstructured":"Bailly C, Carlier T, Berriolo-Riedinger A, et al. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. Haematologica. 2020;105(1):e33\u20136.","journal-title":"Haematologica."},{"issue":"20","key":"5386_CR27","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","volume":"130","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Sch\u00f6der H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130(20):2196\u2013203.","journal-title":"Blood."},{"issue":"2","key":"5386_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11060-010-0182-0","volume":"100","author":"N Kawai","year":"2010","unstructured":"Kawai N, Zhen HN, Miyake K, Yamamaoto Y, Nishiyama Y, Tamiya T. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment. J Neuro-Oncol. 2010;100(2):225\u201332.","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"5386_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2967\/jnumed.112.108654","volume":"54","author":"B Kasenda","year":"2013","unstructured":"Kasenda B, Haug V, Schorb E, et al. 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med. 2013;54(2):184\u201391.","journal-title":"J Nucl Med"},{"issue":"1","key":"5386_CR30","first-page":"9","volume":"37","author":"K Okuyucu","year":"2018","unstructured":"Okuyucu K, Alagoz E, Ince S, Ozaydin S, Arslan N. Can metabolic tumor parameters on primary staging (18)F-FDG PET\/CT aid in risk stratification of primary central nervous system lymphomas for patient management as a prognostic model? Rev Esp Med Nucl Imagen Mol. 2018;37(1):9\u201314.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"8","key":"5386_CR31","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"5386_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0006-291X(90)91263-R","volume":"170","author":"T Yamamoto","year":"1990","unstructured":"Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170(1):223\u201330.","journal-title":"Biochem Biophys Res Commun"},{"issue":"34","key":"5386_CR33","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1038\/sj.onc.1209603","volume":"25","author":"SP Mathupala","year":"2006","unstructured":"Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer\u2019s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25(34):4777\u201386.","journal-title":"Oncogene."},{"issue":"23","key":"5386_CR34","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1158\/0008-5472.CAN-20-2425","volume":"80","author":"K Tateishi","year":"2020","unstructured":"Tateishi K, Miyake Y, Kawazu M, et al. A hyperactive RelA\/p65-hexokinase 2 signaling axis drives primary central nervous system lymphoma. Cancer Res. 2020;80(23):5330\u201343.","journal-title":"Cancer Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05386-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T05:19:22Z","timestamp":1632979162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05386-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["5386"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05386-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed written consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"C.G. reports consulting for BTG International and Kite. The remaining authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}